1. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study;Loehrer;J Clin Oncol,1992
2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees;Horwich;Ann Oncol,2019
3. EAU. EAU guidelines on muscle-invasive and metastatic bladder cancer. https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Muscle-invasive-and-Metastatic-Bladder-Cancer-2019.pdf.
4. ESMO. ESMO eUpdate—bladder cancer treatment recommendations. https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer/eupdate-bladder-cancer-treatment-recommendations2.
5. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol,2000